Search results | forest


Partnering Agreements with Forest

This report provides all the information you require to better understand Forest and its partnering interests and activities over the past seven years.



Forest Laboratories is a top pharmaceutical company based in New York, USA

AstraZeneca rumored to be pursuing Forest Laboratories

British drug maker AstraZeneca recently made an abortive acquisition approach to Forest Laboratories before the specialty-drug company agreed last week to be bought by Actavis for $25 billion, according to people familiar with the matter.

AstraZeneca is eyeing Forest Laboratories for acquisition

AstraZeneca (AZ) is considering a acquisition bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.

Forest M&A deals and alliances 2005-2013

Forest Laboratories has not been very active in the M&A dealmaking. There were two M&A announcements by Forest Laboratories since 2005;

Forest Labs: Partnering activity 2005-2013

Forest Laboratories is a big pharma company active in partnering, licensing and M&A in pharmaceuticals worldwide.

Forest Laboratories: Experimenting with all types of partners and partnering

Forest Laboratories is a large pharmaceutical company developing innovative products focused on a number of diseases including cardiovascular, CNS, mental health and infectious diseases.

Will Allergan and Forest bid for Elan?

Sources suggest that Allergan and Forest will table rival bids to acquire Elan this week

Biotech rumor mill: Forest Laboratories mulls bid for Irish drugmaker Elan

According to the biotech rumor mill Forest Laboratories, a big pharma company, is among a handful of companies interested in bidding for Irish drugmaker Elan, a big biotech company.

Forest: Company profile

Return to top 50 pharma list Summary Website: Headquarters: New York NY, USA Ticker Symbol: FRX (New York Stock Exchange) SEC Link: Forest Pharmaceuticals SEC filings Subsidiaries: Cerexa Top 50 Pharma ranking*: 30 *Ranking based on reported global pharma sales for year ending December 2011. Sales revenue (USD billions) [% change from 2010]: $4.2 [7.36%] R&D spend (USD millions): $715 more »

Real M&A: Forest Labs Seen Needing Deal Amid Patent Loss

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire


Sorry, your search returned no results.


Forest Labs scoops up Furiex Pharma for $1.1 billion

Forest Laboratories and Furiex Pharmaceuticals has entered into a m&a definitive agreement to acquire Furiex for $95 per share, or approximately $1.1 billion in cash.

Biggest M&A deal: Actavis to buy Forest Labs for $25 billion

The biggest m&a deal is to take place where Actavis will acquire Forest laboratories for $25 billion.

Forest Lab offers Senior notes for $1.8 billion financing

Forest Laboratories announced it priced a private placement offering $1.8 billion aggregate principal amount of senior unsecured notes financing.

Forest Laboratories and Aptalis enters into m&a deal

Forest Laboratories has entered into a definitive m&a deal to acquire Aptalis for $2.9 billion in cash from its shareholders.

Big pharma, Forest Lab grabs schizophrenia drugs from Merck

Forest Laboratories, big pharma, announced that is acquiring exclusive rights in the United States for Saphris (asenapine).

Forest in settlement agreement for Bystolic with Glenmark Generics

Forest Laboratories  entered into settlement agreement with a company that wanted marketing approval for a generic version of its blood pressure drug Bystolic.

Forest Laboratories & Adamas Pharmaceuticals ink pharma partners deal for Alzheimers treatment

Forest Laboratories and Adamas Pharmaceuticals have entered into a pharma partners agreement for the development and commercialization of a fixed dosed combination of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer’s type in the United States.

Big pharma Forest settles pharma partnering dispute with Hetero Labs for Bystolic

Forest Laboratories and Forest Laboratories Holdings announced that they have agreed on settlement of their pharma partnering agreement with Hetero Labs Lt and Hetero USA

Pharma partnering ties bring Forest and Moksha8 together

Forest Laboratories have entered into a broad strategic pharma partnering alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market

Real M&A: Forest Labs Seen Needing Deal Amid Patent Loss

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire